Tag Archives: Tandem

Tandem, Amarin, and Intercept Q2 ’22 Earnings Updates; Anthem to Cover Eversense E3 Implantable CGM

A series of cardiometabolic-related news items have been observed: Tandem (press release), Amarin (press release; slides), and Intercept (press release; slides) hosted their respective earnings calls; and Senseonics announced Anthem is now covering implantable CGMs, including Senseonics’s Eversense E3 CGM. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Tandem Acquires Capillary Biomedical; Lilly’s Mounjaro Receives Positive CHMP Opinion

Two cardiometabolic-related news items have been observed: Tandem announced it has acquired Capillary Biomedical; and EMA announced Mounjaro (tirzepatide) received a positive CHMP opinion for the treatment of T2DM in adults. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Senseonics Eversense E3 CGM Receives CE Mark; Tandem Appoints Two New Members to Board of Directors; Akero Announces Financing Transactions with Pfizer and Hercules Capital

Three cardiometabolic-related news items have been observed: Senseonics announced it has received CE Mark for the next-generation Eversense E3 CGM system; Tandem announced the appointment of two new directors to its board; and Akero Therapeutics announced two financing transactions with Pfizer and Hercules Capital. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Tandem, Amarin, and Regeneron Q1 ’22 Earnings Updates

A series of cardiometabolic-related news items have been observed: Tandem (press release), Amarin (press release; slides), and Regeneron (press release; slides) hosted their respective earnings calls. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

ATTD 2022 Key Press Releases (April 27); Abbott, Ypsomed, and CamDiab to develop AID System

On the first day of ATTD 2022, a series of diabetes-related press releases have been observed from Insulet, Welldoc, and Tandem. Separate from the conference, Abbott, Ypsomed, and CamDiab announced a partnership for the development of an AID system. Below, FENIX provides highlights and insights from the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Provention Bio Refiles Teplizumab BLA; Medtronic and Tandem Q4 ’21 and FY ’21 Earnings Updates; Lilly Invests $700M in New Lilly Institute for Genetic Medicine; RosVivo Therapeutics and Lilly Sign MTA for RSVI-301; February 21-24 CHMP Agenda

A series of cardiometabolic-related news items have recently been observed from Provention Bio, Medtronic, Tandem, Lilly, RosVivo Therapeutics, and the CHMP. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Tandem’s Mobile Bolus Feature Cleared by FDA

Tandem announced FDA has cleared its remote bolus insulin dosing feature for its t:connect mobile app. The updated t:connect mobile app provides t:slim X2 insulin pump users the ability to program/cancel bolus insulin requests through their compatible iOS or Android smartphone. Below, FENIX provides brief thoughts on what the launch of the remote bolus feature means for Tandem, Insulet, and Medtronic.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Tandem Hosts 2021 R&D Webinar; FDA Accepts IND for G&L’s Novel GLP-1 Analogue; BD Announces Name of Diabetes Spin Off Company

Three cardiometabolic-related news items have been observed: Tandem hosted its 2021 R&D webinar (view here; slides) and provided an in-depth review of the company’s product pipeline, including the t:slim X3, t:sport (Mobi), and a future patch pump; Gan & Lee announced FDA accepted its IND application for a novel GLP-1 analog, referred to as GZR18; and Becton Dickinson announced that its diabetes spinoff business company will be named “embecta [pronounced em-BECK-tah]. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Lexicon, Tandem, Amarin, Intercept, and Amgen Q3 ’21 Earnings Updates

A series of cardiometabolic-related news items have been observed: Lexicon (press release), Tandem (press release), Amarin (press release; slides), Intercept, (press release; slides), and Amgen (press release; slides), hosted their respective Q3 ’21 earnings calls. Importantly, Lexicon discussed its US sotagliflozin commercial strategy suggesting it is moving forward on its own. Below, FENIX provides highlights and insights from the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Tandem, Ionis, Esperion, and Amgen Q2 ’21 Earnings Updates; Dario Gains National Digital Behavioral Health Contract

Five cardiometabolic-related news items have recently been observed: Tandem, Ionis, Esperion, and Amgen hosted their respective Q2 ‘21 earnings calls; and Dario Health announced it was selected as the digital behavioral health provider for an undisclosed national professional services company. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.